Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PMCB NASDAQ:SCYX NASDAQ:SNTI NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePMCBNuvilex$0.70-3.5%$0.75$0.63▼$1.51$7.79M0.51319,260 shs194,785 shsSCYXSCYNEXIS$4.71-3.5%$6.88$4.52▼$10.48$27.25M1.0562,216 shs65,509 shsSNTISenti Biosciences$0.97-3.5%$0.96$0.77▼$3.88$31.15M2.08201,950 shs225,576 shsTVRDTvardi Therapeutics$2.89-6.2%$3.36$2.75▼$43.65$28.90M0.3346,402 shs80,970 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePMCBNuvilex-0.17%-15.39%-1.04%-3.67%-33.45%SCYXSCYNEXIS+4.50%-17.04%-35.31%-23.75%-35.04%SNTISenti Biosciences+2.53%0.00%+4.82%+3.64%-70.50%TVRDTvardi Therapeutics+4.41%-11.75%-16.53%-21.63%-87.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePMCBNuvilex$0.70-3.5%$0.75$0.63▼$1.51$7.79M0.51319,260 shs194,785 shsSCYXSCYNEXIS$4.71-3.5%$6.88$4.52▼$10.48$27.25M1.0562,216 shs65,509 shsSNTISenti Biosciences$0.97-3.5%$0.96$0.77▼$3.88$31.15M2.08201,950 shs225,576 shsTVRDTvardi Therapeutics$2.89-6.2%$3.36$2.75▼$43.65$28.90M0.3346,402 shs80,970 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePMCBNuvilex-0.17%-15.39%-1.04%-3.67%-33.45%SCYXSCYNEXIS+4.50%-17.04%-35.31%-23.75%-35.04%SNTISenti Biosciences+2.53%0.00%+4.82%+3.64%-70.50%TVRDTvardi Therapeutics+4.41%-11.75%-16.53%-21.63%-87.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePMCBNuvilex 1.00SellN/AN/ASCYXSCYNEXIS 2.00Hold$24.00409.55% UpsideSNTISenti Biosciences 2.80Moderate Buy$8.75806.36% UpsideTVRDTvardi Therapeutics 2.43Hold$53.601,754.67% UpsideCurrent Analyst Ratings BreakdownLatest PMCB, SNTI, SCYX, and TVRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.004/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026SNTISenti Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026TVRDTvardi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/1/2026TVRDTvardi Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.003/30/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ASCYXSCYNEXIS$20.60M1.28N/AN/A$9.07 per share0.52SNTISenti Biosciences$20K1,503.61N/AN/A$0.18 per share5.36TVRDTvardi Therapeutics$7.14M3.80N/AN/A$2.23 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%7/1/2026 (Estimated)SCYXSCYNEXIS-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)SNTISenti Biosciences-$61.44M-$1.92N/AN/AN/AN/A-532.05%-103.35%8/6/2026 (Estimated)TVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/ALatest PMCB, SNTI, SCYX, and TVRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2026N/APMCBNuvilex-$0.06N/AN/AN/AN/AN/A5/14/2026Q1 2026SNTISenti Biosciences-$0.36-$0.14+$0.22-$0.14$0.02 million$0.02 million5/11/2026Q1 2026SCYXSCYNEXIS-$0.80-$3.36-$2.56-$0.42$0.08 millionN/A5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/A3/31/2026Q4 2025TVRDTvardi Therapeutics-$0.55-$0.78-$0.23-$0.78N/AN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPMCBNuvilexN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPMCBNuvilexN/A12.3312.33SCYXSCYNEXISN/A3.943.94SNTISenti BiosciencesN/A1.041.04TVRDTvardi TherapeuticsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPMCBNuvilex34.24%SCYXSCYNEXIS54.37%SNTISenti Biosciences25.70%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipPMCBNuvilex10.98%SCYXSCYNEXIS4.09%SNTISenti Biosciences3.12%TVRDTvardi Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePMCBNuvilex410.74 million9.56 millionOptionableSCYXSCYNEXIS605.58 million5.36 millionOptionableSNTISenti Biosciences431.15 million30.17 millionNot OptionableTVRDTvardi Therapeutics809.38 million8.69 millionN/APMCB, SNTI, SCYX, and TVRD HeadlinesRecent News About These CompaniesTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comTvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comTvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50April 9, 2026 | msn.comBarclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)April 8, 2026 | theglobeandmail.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumApril 2, 2026 | globenewswire.comTvardi: Q4 Earnings SnapshotApril 1, 2026 | stamfordadvocate.comSTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor ConferencesFebruary 12, 2026 | markets.businessinsider.comWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateFebruary 7, 2026 | finance.yahoo.comTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comTvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsJanuary 8, 2026 | markets.businessinsider.comINVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 27, 2025 | newsfilecorp.comNTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 24, 2025 | globenewswire.comINVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 23, 2025 | prnewswire.comTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 21, 2025 | businesswire.comSHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, SNTI, SCYX, and TVRD Company DescriptionsNuvilex NASDAQ:PMCB$0.70 -0.03 (-3.50%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.01 (+0.71%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.SCYNEXIS NASDAQ:SCYX$4.71 -0.17 (-3.48%) Closing price 04:00 PM EasternExtended Trading$4.67 -0.04 (-0.85%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Senti Biosciences NASDAQ:SNTI$0.97 -0.03 (-3.46%) Closing price 04:00 PM EasternExtended Trading$0.96 0.00 (-0.04%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Tvardi Therapeutics NASDAQ:TVRD$2.89 -0.19 (-6.17%) Closing price 04:00 PM EasternExtended Trading$2.88 -0.01 (-0.35%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
